Developability and Candidate Selection


The notion of “kill fast, kill early” has been a motto of the pharmaceutical companies for many years, and today, this same notion is becoming center-stage action for many biopharm companies looking to select the right biologic to move forward, decrease attrition rate in late-stage development and consequently bring down costs and timelines.

The Developability and Candidate Selection conference will look at analytical and profiling techniques to determine the feasibility of molecules for further development, such as evaluation of their physicochemical properties, analysis of their aggregation and immunogenicity risks, and optimization of their properties through engineering and design.

We invite analytical and discovery scientists working on developability, molecular assessment, profiling, candidate selection, early stage R&D, analytical method development, process development, pre-formulation and PKPD to join us and hear about the various techniques and efforts used at various companies to determine a molecule’s candidacy which helped move the right molecule forward.

Early-Confirmed Topics and Speakers include:


DEVELOPABILITY AND MOLECULAR ASSESSMENT DURING EARLY DISCOVERY

Early Discovery Developability and Molecular Assessments to Enable Optimal Candidate Selection

Amy Tam, MSc., Senior Scientist, Global Biotherapeutic Technologies, Pfizer, Inc.

In Vivo Fitness Parameter-Based Ranking of Novel Biologic Drug Candidates during Developability Assessment - Concept, Case Study and a Novel HT FcRn Binding Assay

Torsten Kuiper, Ph.D., Integrated Biologics Profiling, Novartis Pharma AG

Selection of Novel Glycosylated Polypeptide Targets from Controlled Engineered Eukaryotic Display Library

Pranay Khare, Ph.D., Independent Consultant


ANALYTICAL AND COMPUTATIONAL TECHNIQUES FOR PREDICTING DEVELOPABILITY

Using High Throughput Assays to Predict the Fate of an Antibody during Expression, Purification, Storage and Serum Clearance (tentative)

Tingwan Sun, Ph.D., Scientist, Protein Analytics Group, Adimab

Analytical Strategies to Guide Candidate Selection through Developability Assessment (tentative)

Johnson Varghese, Ph.D., Director, Analytical Development, Shire

Predicting Developability-Related Issues with Computational and Experimental Methods

Daniel Seeliger, Ph.D., Research Scientist, Lead Identification and Optimization Support, Boehringer-Ingelheim Pharma GmbH & Co. KG


DEVELOPABILITY ASSESSMENT AND OPTIMIZATION OF NOVEL AND COMPLEX BIOLOGICS

Developability Considerations for Complex Biologics

Hubert Kettenerger, Ph.D., Principal Scientist, Large Molecule Research, Roche Innovation Center Penzberg

Designing Bispecific Antibodies with Improved Developability Properties

Srinath Kasturirangan, Ph.D., Scientist I, Antibody Discovery & Protein Engineering, MedImmune

Revealing the Complicated Relationships between Antibody Fragment Stability, Structural Flexibility, and Allosteric Response

Dennis R. Livesay, Ph.D., Professor, Bioinformatics and Genomics, University of North Carolina at Charlotte




For questions about the meeting, please contact:
Mimi Langley
Sr. Conference Director
Cambridge Healthtech Institute
Phone: 816-472-0701
Email: mlangley@healthtech.com

For partnering & sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5483
Email: jstroup@healthtech.com